Hyperthermic intraperitoneal chemotherapy in serosa-invasive gastric cancer patients.

Hyperthermic intraperitoneal chemotherapy (HIPEC) appears to be helpful in decreasing risks of metachronous peritoneal metastases (MPM) and has a potential for improving the survival rate in radically operated gastric cancer patients. HIPEC administration made it possible to attain a statistically significant reduction in the cumulative incidence of MPM.